The latest Business updates from the science industry
by Heather Hobbs Merger Brings Opportunities in Materials Characterisation
The acquisition also offers both companies access to new markets and opportunities in:
- Particle Size and shape from 0.3nm to 135mm, - Surface and Pore Size Distribution using both Physi- and Chemisorption, - Catalyst Analysis - Porosity and Density measurements - Dispersion Stability and Zeta Potential Analysis - Curing and Drying Analysis - Rheological Properties
Gerard Meunier, CEO of Formulaction (left) and Andries Verder, owner of the Verder Group
French laboratory equipment provider Formulaction SA has been acquired by the Verder Group and will be integrated into the organisation’s Microtrac MRB division, a leading manufacturer of particle characterisation systems.
A recognised innovator in the fi eld of laboratory equipment for analysing dispersion stability & shelf life, curing and drying processes and rheology, the addition of Formulaction to the Microtrac MRB portfolio will create a comprehensive suite of instrumentation for materials characterisation practitioners, complementing the group’s existing capabilities in laser diffraction, dynamic light scattering, image analysis and gas adsorption analysis instruments.
CEO of Formulaction, Gerard Meunier said: “Since its creation Formulaction has been at the forefront of technical innovation in helping scientists to directly assess key properties of their materials from early development to fi nal product design or ‘End Use Properties’. The integration of the Formulaction product portfolio into Microtrac MRB opens huge opportunities for the expanded group to provide added value to customers in their pursuit of innovative product development by delivering high quality solutions.”
Verder CEO, Andries Verder stated: “We have been witnessing the development of Formulaction for years and are impressed with the technology and the agility of the team. The addition of the people and products from Formulaction is an important building block in our drive to enable the progress for our customers in the world of particle characterisation.”
More information online:
ilmt.co/PL/k1M8 60389pr@reply-direct.com
Acquisition Enhances Environmental Diagnostics Services
Global public health and toxicology diagnostics business Clinisys has acquired Promium, a Washington-based provider of laboratory information management systems dedicated to supporting environmental, water, wastewater and other analytical testing laboratories that protect health and safety.
The acquisition provides an extra layer of industry expertise, knowledge and proven technology to Clinisys’ vision of enabling healthier and safer communities as a global provider of intelligent diagnostic informatics solutions.
“Promium is a great fi t with Clinisys. The addition of its team expands our knowledge and customers in environmental, water quality and wastewater laboratories,” said Clinisys’ CEO Michael Simpson. “Promium shares our deep belief that the future of improved public health is ensuring the highest safety in the food that we eat, water we drink and in the environments in which we live. We are now poised to help the applied sciences laboratories provide the safest and most effi cient solutions possible.”
“Our 300+ environmental, water and wastewater laboratory customers will benefi t from Clinisys’ scale and latest technology to streamline their workfl ows and improve testing and monitoring,” said Scot Cocanour, CEO and founder of Promium. “Modern applied sciences laboratories need the very best technology platforms for maximum effi ciency, quality and compliance. Joining Clinisys assures Promium customers of those benefi ts into the future.”
All current Promium customers will continue to be supported as normal. Over time, the Promium Element LIMS solution will be integrated into the Clinisys Laboratory Solutions family as the business accelerates the roadmap for its next-generation SaaS product strategy.
More information online:
ilmt.co/PL/9RVR 60388pr@reply-direct.com
Michael Simpson, CEO Clinisys
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188
